Patients hospitalized with COVID-19 often report a wide range of symptoms months after their initial illness. But a new study ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

This infectious respiratory illness is on the rise, especially among children. Here's what parents need to know.

Former Malaysian Prime Minister Mahathir Mohamad has been admitted to hospital for a respiratory infection, his office said ...

Using cutting-edge breath sampling, scientists have achieved a breakthrough in diagnosing lower respiratory tract infections with an in vitro assay that could transform patient care in ICUs worldwide.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

A mother’s worst nightmare is watching her child fall gravely ill, feeling helpless as the condition becomes worse. When ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...

Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...